相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Gene expression profiling of chromophobe renal cell carcinomas and renal oncocytomas by Affymetrix GeneChip using pooled and individual tumours
Maria V. Yusenko et al.
International Journal of Biological Sciences (2012)
The Mammalian Target of Rapamycin Pathway Is Widely Activated Without PTEN Deletion in Renal Cell Carcinoma Metastases
Tamer Abou Youssif et al.
CANCER (2011)
The Role of Epigenetic Transcription Repression and DNA Methyltransferases in Cancer
Filipe Ivan Daniel et al.
CANCER (2011)
Survival After Complete Surgical Resection of Multiple Metastases From Renal Cell Carcinoma
Angela L. Alt et al.
CANCER (2011)
Chromosomal Instability Confers Intrinsic Multidrug Resistance
Alvin J. X. Lee et al.
CANCER RESEARCH (2011)
Durable Remission of Metastatic Renal Cell Carcinoma With Gemcitabine and Capecitabine After Failure of Targeted Therapy
Stephen L. Richey et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Pazopanib Efficacy in Renal Cell Carcinoma: Evidence for Predictive Genetic Markers in Angiogenesis-Related and Exposure-Related Genes
Chun-Fang Xu et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib
Brian I. Rini et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
Metastasectomy After Targeted Therapy in Patients With Advanced Renal Cell Carcinoma
Jose A. Karam et al.
JOURNAL OF UROLOGY (2011)
Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma
Ignacio Varela et al.
NATURE (2011)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine
M. Gerlinger et al.
BRITISH JOURNAL OF CANCER (2010)
Cancer Statistics, 2010
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2010)
Safety and Efficacy Results of the Advanced Renal Cell Carcinoma Sorafenib Expanded Access Program in North America
Walter M. Stadler et al.
CANCER (2010)
Sunitinib Acts Primarily on Tumor Endothelium rather than Tumor Cells to Inhibit the Growth of Renal Cell Carcinoma
Dan Huang et al.
CANCER RESEARCH (2010)
Biomarkers Predicting Outcome in Patients with Advanced Renal Cell Carcinoma: Results from Sorafenib Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial
Carol Pena et al.
CLINICAL CANCER RESEARCH (2010)
Understanding the molecular genetics of renal cell neoplasia: implications for diagnosis, prognosis and therapy
Liang Cheng et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2010)
Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
Julie R. Brahmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
Cora N. Sternberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Histological Subtype is an Independent Predictor of Outcome for Patients With Renal Cell Carcinoma
Bradley C. Leibovich et al.
JOURNAL OF UROLOGY (2010)
The promise of biomarkers for personalized renal cancer care
Prasad Devarajan
KIDNEY INTERNATIONAL (2010)
Predictive value of baseline serum vascular endothelial growth factor and neutrophil gelatinase-associated lipocalin in advanced kidney cancer patients receiving sunitinib
Camillo Porta et al.
KIDNEY INTERNATIONAL (2010)
Is advanced renal cell carcinoma becoming a chronic disease?
James Larkin et al.
LANCET (2010)
Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes
Gillian L. Dalgliesh et al.
NATURE (2010)
Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR.
Makoto Maemondo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Anaplastic Lymphoma Kinase Inhibition in Non-Small-Cell Lung Cancer
Eunice L. Kwak et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer
T. Sato et al.
ONCOGENE (2010)
Differential diagnosis of renal tumours with clear cell histology
Victor E. Reuter et al.
PATHOLOGY (2010)
Prognostic and predictive biomarkers in renal cell carcinoma
Michael M. Vickers et al.
TARGETED ONCOLOGY (2010)
Multi-modal treatment for metastatic renal cancer: the role of surgery
Paul Russo
WORLD JOURNAL OF UROLOGY (2010)
Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets
Charles Swanton et al.
GENOME MEDICINE (2010)
Accuracy of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in Diagnosis and Prognosis in Acute Kidney Injury: A Systematic Review and Meta-analysis
Michael Haase et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2009)
Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma
P. Bono et al.
ANNALS OF ONCOLOGY (2009)
Analysis of PTEN and HIF-1α and Correlation With Efficacy in Patients With Advanced Renal Cell Carcinoma Treated With Temsirolimus Versus Interferon-α
Robert A. Figlin et al.
CANCER (2009)
Mutant Metabolic Enzymes Are at the Origin of Gliomas
Hai Yan et al.
CANCER RESEARCH (2009)
Pazopanib: an antiangiogenic drug in perspective
Carlos A. Castaneda et al.
FUTURE ONCOLOGY (2009)
Cytogenetic Profile Predicts Prognosis of Patients With Clear Cell Renal Cell Carcinoma
Tobias Klatte et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Metastatic Sarcomatoid Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor-Targeted Therapy
Ali Reza Golshayan et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Hypoxia inducible factor-1α correlates with vascular endothelial growth factor A and C indicating worse prognosis in clear cell renal cell carcinoma
Gordana Orevic et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2009)
Cathepsin-K immunoreactivity distinguishes MiTF/TFE family renal translocation carcinomas from other renal carcinomas
G. Martignoni et al.
MODERN PATHOLOGY (2009)
Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial
Martin E. Gore et al.
LANCET ONCOLOGY (2009)
Effect of temsirolimus versus interferon-α on outcome of patients with advanced renal cell carcinoma of different tumor histologies
Janice P. Dutcher et al.
MEDICAL ONCOLOGY (2009)
Clinical Trial Experience With Temsirolimus in Patients With Advanced Renal Cell Carcinoma
Gary R. Hudes et al.
SEMINARS IN ONCOLOGY (2009)
Hypoxia upregulates the histone demethylase JMJDIA via HIF-1
Sven Wellmann et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2008)
The indication for postchemotherapy lymph node dissection in clinical stage IS nonseminomatous germ cell tumor
Atreya Dash et al.
CANCER (2008)
HIF-α Effects on c-Myc Distinguish Two Subtypes of Sporadic VHL-Deficient Clear Cell Renal Carcinoma
John D. Gordan et al.
CANCER CELL (2008)
Tissue-based research in kidney cancer: Current challenges and future directions
Sabina Signoretti et al.
CLINICAL CANCER RESEARCH (2008)
Magnetic resonance imaging - Measured blood flow change after antiangiogenic therapy with PTK787/ZK 222584 correlates with clinical outcome in metastatic renal cell carcinoma
Cedric de Bazelaire et al.
CLINICAL CANCER RESEARCH (2008)
The Histone Demethylases JMJD1A and JMJD2B Are Transcriptional Targets of Hypoxia-inducible Factor HIF
Sophie Beyer et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma
Olwen M. Hahn et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma
Brian I. Rini et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206
Brian I. Rini et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Germline SDHB mutations and familial renal cell carcinoma
Christopher Ricketts et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents
Nizar M. Tannir et al.
JOURNAL OF UROLOGY (2008)
Efficacy of everolimus in advanced renal cell carcinoma:: a double-blind, randomised, placebo-controlled phase III trial
Robert J. Motzer et al.
LANCET (2008)
Modes of resistance to anti-angiogenic therapy
Gabriele Bergers et al.
NATURE REVIEWS CANCER (2008)
Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma
Toni K. Choueiri et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Use of Von-Hippel Lindau (VHL) mutation status to predict objective response to vascular endothelial growth factor (VEGF) - targeted therapy in metastatic renal cell carcinoma (RCC)
T. K. Choueiri et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Hypoxia-inducible factor 1α in clear cell renal cell carcinoma
Tobias Klatte et al.
CLINICAL CANCER RESEARCH (2007)
Cytoreductive nephron-sparing surgery does not appear to undermine disease-specific survival in patients with metastatic renal cell carcinoma
Georg C. Hutterer et al.
CANCER (2007)
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
Bernard Escudier et al.
LANCET (2007)
Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma
Bradley C. Leibovich et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Associations of single nucleotide polymorphisms in the vascular endothelial growth factor gene with the characteristics and prognosis of renal cell carcinomas
Yoshihisa Kawai et al.
EUROPEAN UROLOGY (2007)
Prognostic impact of carbonic anhydrase IX expression in human renal cell carcinoma
Johanna Sandlund et al.
BJU INTERNATIONAL (2007)
Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma
Daniel Cho et al.
CLINICAL GENITOURINARY CANCER (2007)
Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins
Samuel E. DePrimo et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2007)
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
Gary Hudes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Detection of DNA copy number changes and oncogenic signaling abnormalities from gene expression data reveals MYC activation in high-grade papillary renal cell carcinoma
Kyle A. Furge et al.
CANCER RESEARCH (2007)
Interleukin-4 promoter polymorphisms: A genetic prognostic factor for survival in metastatic renal cell carcinoma
Thomas Kleinrath et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Estimates of the cancer incidence and mortality in Europe in 2006
J. Ferlay et al.
ANNALS OF ONCOLOGY (2007)
The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma
William G. Kaelin
CLINICAL CANCER RESEARCH (2007)
Sorafenib in advanced clear-cell renal-cell carcinoma
Bernard Escudier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Serum neutrophil gelatinase-associated lipocalin as a marker of renal function in children with chronic kidney disease
Mark M. Mitsnefes et al.
PEDIATRIC NEPHROLOGY (2007)
Somatic von Hippel-Lindau (VHL) gene analysis and clinical outcome under antiangiogenic treatment in metastatic renal cell carcinoma: preliminary results
Sophie Gad et al.
TARGETED ONCOLOGY (2007)
Patients with metastatic renal cell carcinoma with long-term disease-free survival after treatment with sunitinib and resection of residual metastases
Brian I. Rini et al.
CLINICAL GENITOURINARY CANCER (2006)
Hypoxia-inducible factor lot expression in renal cell carcinoma analyzed by tissue microarray
Anders Lidgren et al.
EUROPEAN UROLOGY (2006)
When translation meets transformation: the mTOR story
J. Averous et al.
ONCOGENE (2006)
A phase II study of gemcitabine and capecitabine in metastatic renal cancer - A report of cancer and leukemia group B protocol 90008
Walter M. Stadler et al.
CANCER (2006)
Role of hypoxia-inducible factor (HIF)-1α-versus HIF-2α in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-1, or loss of von Hippel-Lindau function:: Implications for targeting the HIF pathway
Veronica A. Carroll et al.
CANCER RESEARCH (2006)
Antianglogenic potential of the mammalian target of rapamycin inhibitor temsirolimus
Donatella Del Bufalo et al.
CANCER RESEARCH (2006)
Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up
RH Thompson et al.
CANCER RESEARCH (2006)
Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer
GV Thomas et al.
NATURE MEDICINE (2006)
Mucinous tubular and spindle cell carcinoma:: a report of 15 cases and a review of the literature
S Ferlicot et al.
VIRCHOWS ARCHIV (2005)
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
MJ Piccart-Gebhart et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: Novel role of fumarate in regulation of HIF stability
JS Isaacs et al.
CANCER CELL (2005)
Tyrosine kinases as targets for cancer therapy
DS Krause et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Erlotinib in previously treated non-small-cell lung cancer
FA Shepherd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Tumor suppressor activity and epigenetic inactivation of hepatocyte growth factor activator inhibitor type 2/SPINT2 in papillary and clear cell renal cell carcinoma
MR Morris et al.
CANCER RESEARCH (2005)
Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer
M Atkins et al.
CLINICAL CANCER RESEARCH (2005)
Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma
TM Mekhail et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase
MA Selak et al.
CANCER CELL (2005)
Cytoreductive nephrectomy in patients with metastatic renal cancer: A combined analysis
RC Flanigan et al.
JOURNAL OF UROLOGY (2004)
Role of VHL gene mutation in human cancer
WY Kim et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Phase II clinical trial of capecitabine and gemcitabine chemotherapy in patients with metastatic renal carcinoma
JS Waters et al.
BRITISH JOURNAL OF CANCER (2004)
mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E
DC Fingar et al.
MOLECULAR AND CELLULAR BIOLOGY (2004)
Overexpression of KIT (CD117) in chromophobe renal cell carcinoma and renal oncocytoma
CC Pan et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2004)
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
SM Wilhelm et al.
CANCER RESEARCH (2004)
A multifactorial postoperative surveillance model for patients with surgically treated clear cell renal cell carcinoma
I Frank et al.
JOURNAL OF UROLOGY (2003)
Rhebbing up mTOR - New insights on TSC1 and TSC2, and the pathogenesis of tuberous sclerosis
DJ Kwiatkowski
CANCER BIOLOGY & THERAPY (2003)
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer
JC Yang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Mutations in the Fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America
JR Toro et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2003)
SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo
AM O'Farrell et al.
BLOOD (2003)
Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma - A stratification tool for prospective clinical trials
BC Leibovich et al.
CANCER (2003)
Overexpression of KIT in chromophobe renal cell carcinoma
K Yamazaki et al.
ONCOGENE (2003)
PRCC-TFE3 renal carcinomas -: Morphologic, immunohistochemical, ultrastructural, and molecular analysis of an entity associated with the t(X;1)(p11.2;q21)
P Argani et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2002)
Low-grade tubular-mucinous renal neoplasms:: Morphologic, immunohistochemical, and genetic features
C Rakozy et al.
MODERN PATHOLOGY (2002)
Regulation of hypoxia-inducible factor 1α expression and function by the mammalian target of rapamycin
CC Hudson et al.
MOLECULAR AND CELLULAR BIOLOGY (2002)
Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology
RJ Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer
K Yu et al.
ENDOCRINE-RELATED CANCER (2001)
A distinctive pediatric renal neoplasm characterized by epithelioid morphology, basement membrane production, focal HMB45 immunoreactivity, and t(6;11)(p21.1;q12) chromosome translocation
P Argani et al.
AMERICAN JOURNAL OF PATHOLOGY (2001)
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the philadelphia chromosome.
BJ Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Sarcomatoid differentiation in renal cell carcinoma - A study of 101 cases
M de Peralta-Venturina et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2001)
TOR, a central controller of cell growth
T Schmelzle et al.
CELL (2000)
Activation of HIF1α ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex
T Kamura et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel-Lindau protein
M Ohh et al.
NATURE CELL BIOLOGY (2000)
Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer
BI Rini et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
分享论文
